Novel approaches for the treatment of psoriasis

被引:19
作者
DiSepio, D [1 ]
Chandraratna, RAS
Nagpal, S
机构
[1] Allergan Pharmaceut Inc, Dept Biol, Retinoid Res, Irvine, CA 92623 USA
[2] Allergan Pharmaceut Inc, Dept Chem, Retinoid Res, Irvine, CA 92623 USA
关键词
D O I
10.1016/S1359-6446(99)01335-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Psoriasis is a common skin disease affecting similar to 2% of the population. For those who contract the disease it is usually recurrent and sometimes very debilitating. The cause of psoriasis is unknown, although it appears to be an autoimmune disease with a likelihood for genetic predisposition. Past topical treatments such as emollients, coal tar and dithranol have been messy, cosmetically unacceptable and of low efficacy, while systemic therapies such as methotrexate, cyclosporin and acitretin have suffered from significant side effects. New therapies based on medicinal chemistry and an increased understanding of psoriasis have brought us closer to the goal of safe and efficacious treatment of the disease. The authors review some of these new topical and systemic therapies currently in use or in development.
引用
收藏
页码:222 / 231
页数:10
相关论文
共 109 条
[1]  
[Anonymous], 1996, Arch Dermatol, V132, P419
[2]   IL-10 is a key cytokine in psoriasis -: Proof of principle by IL-10 therapy:: A new therapeutic approach [J].
Asadullah, K ;
Sterry, W ;
Stephanek, K ;
Jasulaitis, D ;
Leupold, M ;
Audring, H ;
Volk, HD ;
Döcke, WD .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :783-794
[3]   THE ROLE OF THE IMMUNE-SYSTEM IN THE PATHOGENESIS OF PSORIASIS [J].
BAADSGAARD, O ;
FISHER, G ;
VOORHEES, JJ ;
COOPER, KD .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 95 (05) :S32-S34
[4]   Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4 [J].
Bachelez, H ;
Flageul, B ;
Dubertret, L ;
Fraitag, S ;
Grossman, R ;
Brousse, N ;
Poisson, D ;
Knowles, RW ;
Wacholtz, MC ;
Haverty, TP ;
Chatenoud, L ;
Bach, JF .
JOURNAL OF AUTOIMMUNITY, 1998, 11 (01) :53-62
[5]   Administration of DAB389IL-2 to patients with recalcitrant psoriasis:: A double-blind, phase II multicenter trial [J].
Bagel, J ;
Garland, WT ;
Breneman, D ;
Holick, M ;
Littlejohn, TW ;
Crosby, D ;
Faust, H ;
Fivenson, D ;
Nichols, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (06) :938-944
[6]   CLONING AND EXPRESSION OF FULL-LENGTH CDNA-ENCODING HUMAN VITAMIN-D RECEPTOR [J].
BAKER, AR ;
MCDONNELL, DP ;
HUGHES, M ;
CRISP, TM ;
MANGELSDORF, DJ ;
HAUSSLER, MR ;
PIKE, JW ;
SHINE, J ;
OMALLEY, BW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (10) :3294-3298
[7]   THE EFFECTS OF CYCLOSPORINE-A ON LYMPHOCYTE-T AND DENDRITIC CELL SUBPOPULATIONS IN PSORIASIS [J].
BAKER, BS ;
GRIFFITHS, CEM ;
LAMBERT, S ;
POWLES, AV ;
LEONARD, JN ;
VALDIMARSSON, H ;
FRY, L .
BRITISH JOURNAL OF DERMATOLOGY, 1987, 116 (04) :503-510
[8]   CD23-mediated nitric oxide synthase pathway induction in human keratinocytes is inhibited by retinoic acid derivatives [J].
Becherel, PA ;
LeGoff, L ;
Ktorza, S ;
Chosidow, O ;
Frances, C ;
Issaly, F ;
MenciaHuerta, JM ;
Debre, P ;
Mossalayi, MD ;
Arock, M .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (06) :1182-1186
[9]   ABNORMAL SEQUENCE OF EXPRESSION OF DIFFERENTIATION MARKERS IN PSORIATIC EPIDERMIS - INVERSION OF 2 STEPS IN THE DIFFERENTIATION PROGRAM [J].
BERNARD, BA ;
ASSELINEAU, D ;
SCHAFFARDESHAYES, L ;
DARMON, MY .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1988, 90 (06) :801-805
[10]  
BERTHJONES J, 1996, BR J CLIN PRACT S, V83, P1